CHECKMATE PHARMACEUTICALS IN (CMPI) Stock Analyst Ratings
USA - NASDAQ:CMPI - US1628181083 - Common Stock
10.5
+0.02 (+0.19%)
ChartMill assigns a Buy % Consensus number of 83% to CMPI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.75. This target is 21.43% above the current price.
CMPI was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CMPI.
In the previous month the buy percentage consensus was at a similar level.
CMPI was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-04-20 | BTIG | Downgrade | Buy -> Neutral |
| 2021-10-06 | B of A Securities | Upgrade | Neutral -> Buy |
CHECKMATE PHARMACEUTICALS IN / CMPI FAQ
What do analysts expect the price target to be for CHECKMATE PHARMACEUTICALS IN (CMPI)?
8 analysts have analysed CMPI and the average price target is 12.75 null. This implies a price increase of 21.43% is expected in the next year compared to the current price of 10.5.
How do analysts rate CHECKMATE PHARMACEUTICALS IN (CMPI)?
The consensus rating for CHECKMATE PHARMACEUTICALS IN (CMPI) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.